Oncogene

Journal PubWeight™ 20372.04‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Activators and target genes of Rel/NF-kappaB transcription factors. 1999 13.46
2 Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. 2007 11.85
3 MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. 2007 10.79
4 Cisplatin: mode of cytotoxic action and molecular basis of resistance. 2003 10.74
5 The Bcl-2 apoptotic switch in cancer development and therapy. 2007 10.08
6 TGF-beta and epithelial-to-mesenchymal transitions. 2005 10.02
7 PI3K pathway alterations in cancer: variations on a theme. 2008 9.94
8 miR-21-mediated tumor growth. 2006 9.90
9 The p53 pathway: positive and negative feedback loops. 2005 9.75
10 EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. 2010 9.66
11 STATs in oncogenesis. 2000 8.60
12 MAP kinase signalling pathways in cancer. 2007 8.52
13 Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. 2009 8.01
14 Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. 2004 7.92
15 MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. 2003 7.90
16 Introduction to NF-kappaB: players, pathways, perspectives. 2006 7.78
17 FOXO transcription factors at the interface between longevity and tumor suppression. 2005 7.50
18 The Bcl-2 family: roles in cell survival and oncogenesis. 2003 7.41
19 MYC oncogenes and human neoplastic disease. 1999 7.28
20 Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. 1994 7.24
21 Histone deacetylase inhibitors: molecular mechanisms of action. 2007 7.13
22 Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. 2002 7.04
23 mir-29 regulates Mcl-1 protein expression and apoptosis. 2007 7.02
24 Regulation of the G2/M transition by p53. 2001 7.02
25 DNA methylation in cancer: too much, but also too little. 2002 6.96
26 Autophagy as a cell death and tumor suppressor mechanism. 2004 6.92
27 BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. 2008 6.82
28 Perturbations of the AKT signaling pathway in human cancer. 2005 6.64
29 Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. 2006 6.61
30 Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. 2006 6.61
31 MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. 2007 6.55
32 Glycolysis inhibition for anticancer treatment. 2006 6.55
33 Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. 2006 6.54
34 The role of STATs in transcriptional control and their impact on cellular function. 2000 6.42
35 Differential regulation and properties of MAPKs. 2007 6.36
36 The FoxO code. 2008 6.22
37 Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. 2002 6.17
38 AP-1 in cell proliferation and survival. 2001 6.07
39 CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. 2002 5.96
40 Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. 2006 5.86
41 The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. 2008 5.85
42 Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. 2009 5.81
43 TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. 2007 5.79
44 DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. 2005 5.74
45 Increasing complexity of Ras signaling. 1998 5.71
46 Widespread deregulation of microRNA expression in human prostate cancer. 2007 5.70
47 Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. 1997 5.64
48 NF-kappaB and the immune response. 2006 5.62
49 Aberrant rel/nfkb genes and activity in human cancer. 1999 5.62
50 Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. 2005 5.50
Next 50